Virtual attendance at US biotech events is projected to surge by 15% in early 2025, driven by accessibility and cost-effectiveness, profoundly impacting financial strategies and market reach.

The 2025 US biotech event landscape presents a dynamic intersection of investor-driven conferences and scientific symposia, each catering to distinct objectives and fostering different types of collaborations crucial for industry growth and innovation.